Abstract
Stroke strikes often suddenly, causes long-term disability and death, and is a huge economical burden for the society, not to mention the human tragedy for the patient and the family. At least 15% of stroke survivors will have a second stroke during the next five years, quarter of which prove out to be fatal within four weeks [1]. Secondary prevention of ischemic stroke (IS) targets at reducing stroke recurrence by means of 1) detection and modification of risk factors, 2) antithrombotic or anticoagulant treatment, and 3) surgical interventions for selected patient subgroups. In this review we will discuss these issues in detail and also offer our personal suggestions for treatment choices. Detecting and treating the modifiable risk factors is the major challenge of secondary prevention of IS.
Keywords: stroke, prevention, cerebrovascular disease, risk factors, antithrombotic agents, brain infarct, endarterectomy
Current Drug Targets
Title: Secondary Prevention of Ischemic Stroke
Volume: 5 Issue: 5
Author(s): Kirsi Rantanen and Turgut Tatlisumak
Affiliation:
Keywords: stroke, prevention, cerebrovascular disease, risk factors, antithrombotic agents, brain infarct, endarterectomy
Abstract: Stroke strikes often suddenly, causes long-term disability and death, and is a huge economical burden for the society, not to mention the human tragedy for the patient and the family. At least 15% of stroke survivors will have a second stroke during the next five years, quarter of which prove out to be fatal within four weeks [1]. Secondary prevention of ischemic stroke (IS) targets at reducing stroke recurrence by means of 1) detection and modification of risk factors, 2) antithrombotic or anticoagulant treatment, and 3) surgical interventions for selected patient subgroups. In this review we will discuss these issues in detail and also offer our personal suggestions for treatment choices. Detecting and treating the modifiable risk factors is the major challenge of secondary prevention of IS.
Export Options
About this article
Cite this article as:
Rantanen Kirsi and Tatlisumak Turgut, Secondary Prevention of Ischemic Stroke, Current Drug Targets 2004; 5 (5) . https://dx.doi.org/10.2174/1389450043345425
DOI https://dx.doi.org/10.2174/1389450043345425 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
Therapeutic Chemical and RNA Design with Artificial Intelligence
Computer-Aided Drug Design (CADD) has emerged as a fundamental component of modern drug discovery. Molecular docking facilitates virtual screening on a large scale through structural simulations. However, traditional CADD approaches face significant limitations, as they can only screen known compounds from existing libraries. PubChem, as the most widely used chemical ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Synthetic and Natural Protease Inhibitors Provide Insights into Parasite Development, Virulence and Pathogenesis
Current Medicinal Chemistry Mitochondria as a Therapeutic Target in Alzheimers Disease and Diabetes
CNS & Neurological Disorders - Drug Targets Chymase Inhibitors
Current Pharmaceutical Design Virus-Associated Vasculitides
Current Immunology Reviews (Discontinued) Targeting the Toll-System in Cardiovascular Sciences
Recent Patents on Inflammation & Allergy Drug Discovery Mitochondrial Alterations and Neuropsychiatric Disorders
Current Medicinal Chemistry Comparison between Atorvastatin and Rosuvastatin on Secondary Percutaneous Coronary Intervention Rate and the Risk Factors in Patients with Coronary Heart Disease
Current Drug Metabolism Endothelial Progenitor Cells at the Interface of Chronic Kidney Disease: From Biology to Therapeutic Advancement
Current Medicinal Chemistry Mesenchymal Stem Cells: New Approaches for the Treatment of Neurological Diseases
Current Stem Cell Research & Therapy Electrochemical Study of DNA Damaged by Oxidation Stress
Combinatorial Chemistry & High Throughput Screening Management of Chemotherapy Induced Cardiomyopathy
Current Cardiology Reviews Ectodomain Shedding of ACE and ACE2 as Regulators of Their Protein Functions
Current Enzyme Inhibition Drug Therapy of Neuropathic Pain: Current Developments and Future Perspectives
Current Drug Targets UHPLC-ESI-QToF Analysis of Trandolapril and Verapamil Hydrochloride in Dosage Form and Spiked Human Plasma Using Solid Phase Extraction: Stability Indicating Assay Method
Current Pharmaceutical Analysis Antiplatelet and Anticoagulation Strategies in the Prevention and Treatment of Ischemic Stroke
Current Pharmaceutical Design Cardioprotective Effects of Indian Gooseberry (Emblica officinalis Gaertn) and its Phytochemicals: A Review
Current Nutrition & Food Science Metalloproteinases and Metalloproteinase Inhibitors in Age-Related Diseases
Current Pharmaceutical Design Inhibition of Sphingomyelin Hydrolysis: Targeting the Lipid Mediator Ceramide as a Key Regulator of Cellular Fate
Current Medicinal Chemistry Medicinal Plants and Bioactive Compounds for Diabetes Management: Important Advances in Drug Discovery
Current Pharmaceutical Design Expression of Circulating miR-21 and -29 and their Association with Myocardial Fibrosis in Hypertrophic Cardiomyopathy
Current Medicinal Chemistry